ProteinSimple Appoints Joe Keegan and Chris van Ingen to its Board of Directors

SANTA CLARA, Calif., March 24, 2014 /PRNewswire/ -- ProteinSimple announced today the appointments of two independent members of the company's Board of Directors, Mr. Chris van Ingen and Dr. Joe Keegan. 

"Chris and Joe are two of the most respected leaders in the life science tool industry," commented Tim Harkness, CEO of ProteinSimple.  "They bring tremendous depth of experience and knowledge about building successful life science technology companies.  We are privileged to have them join our team."

About Joe Keegan

Dr. Keegan brings more than 30 years of experience managing high growth life science businesses. Most recently, he served as the CEO of ForteBio where he transformed the company from a startup in 2007 to a fast growing leader in label-free protein analysis.  ForteBio was acquired in 2012 by Pall Corporation. Previously, Dr. Keegan was the CEO of Molecular Devices (MDC). During his 9-year tenure at MDC, Dr. Keegan grew the company's revenue from $30 million to $185 million, at which point the company was sold to MDS, Inc. for $615 million. Prior to MDC, Dr. Keegan served as President of Worldwide Tissue Culture of Becton Dickinson and Vice President of Microscope and Scientific Instruments Division of Leica.  He currently serves on the Board of Directors of ALDA as Immediate Past Chairman, Advanced Cell Diagnostics, Labcyte Corporation as Chairman, Response Biomedical Corp, Seahorse Bioscience Inc., Stereotaxis, Inc. and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

About Chris van Ingen

Mr. van Ingen has over two decades of senior management leadership experience and has served as an advisor to many life science companies.  Most recently as President of Agilent Technologies' Bio-Analytical Measurement business, he oversaw the growth of that business from $1 billion to over $2 billion in annual revenues in less than 6 years. Mr. van Ingen currently serves on the Board of Directors of Bruker EST, Inc., Accelrys, Inc., as Chairman, and Promega Corporation. In addition, Mr. van Ingen serves as a strategic consultant to several companies in the Life Sciences and Chemical Analysis instrumentation industry.  He previously served as a Director of Alpha Innotech Corporation and Symyx Technologies, Inc. until its merger with Accelrys in July 2010. Mr. van Ingen holds a B.S. degree in analytical chemistry.

About ProteinSimple

Our goal is simply to help researchers gain a better understanding of proteins and their role in disease.  We develop and commercialize proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins.  We believe that traditional protein analysis tools can be overly complex or inadequate, and our goal is to make protein analysis simpler, more quantitative and affordable.  Our comprehensive portfolio of tools includes Simple Western systems that provide fresh insight into protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.  We have over 180 employees, 14,000 systems installed around the world and our headquarters is in Santa Clara, California.  For more information, visit www.proteinsimple.com.

SOURCE ProteinSimple